Gagne, Joshua J.
Polinski, Jennifer M.
Jiang, Wenlei
Dutcher, Sarah K.
Xie, Jing
Lii, Joyce
Fulchino, Lisa A.
Kesselheim, Aaron S.
Funding for this research was provided by:
U.S. Food and Drug Administration
Article History
First Online: 8 February 2017
Change Date: 8 March 2018
Change Type: Correction
Change Details: <b>Page 432, Fig. 2</b> Plots of model-based outcome incidence rates (per 100 person-years of exposure) before and after introduction of first generic versions of study and control drugs.
Compliance with Ethical Standards
:
: Dr. Gagne is Principal Investigator on research funding to the Brigham and Women’s Hospital from the US Food and Drug Administration, the Patient-Centered Outcomes Research Institute, the Agency for Healthcare Research & Quality, FDA Office of Generic Drugs, and Novartis Pharmaceuticals Corporation. He is a consultant to Aetion, Inc. and Optum, Inc. Dr. Polinski is a current employee of CVS Health, but was an employee of Brigham and Women’s Hospital at the time that this research was conducted. Drs. Jiang and Dutcher are employees of the US Food and Drug Administration. Dr. Xie is currently an employee of Sanofi US, but was an employee of Brigham and Women’s Hospital at the time that this research was conducted. Dr. Kesselheim also receives research funding from the Greenwall Faculty Scholar in Bioethics, and the Harvard Program in Therapeutic Science.
: This study was funded by the US Food and Drug Administration Office of Generic Drugs (U01FD004856). Views expressed in this publication do not necessarily reflect the official policies of the Department of Health and Human Services, nor does any mention of trade names, commercial practices, or organization imply endorsement of the United States Government.